Visitors Now:
Total Visits:
Total Stories:
Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Catabasis Pharmaceuticals reports positive pre-clinical data for DMD treatment

Wednesday, January 4, 2017 7:33
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Shares in Catabasis Pharmaceuticals Inc (NASDAQ:CATB) advanced as it reported positive pre-clinical data for the treatment of muscle-wasting disease Duchenne muscular dystrophy (DMD).

The data comes from the edasalonexent programme, which showed two inhibitors edasalonexent (CAT-1004) and CAT-1041 are effective in making better the dystrophic process in two animal models.

Dr H Lee Sweeney, who led the research, said: “There remains a large unmet need in Duchenne for therapies that can treat all affected boys and slow disease progression.

“The orally bioavailable NF-kB inhibitors, edasalonexent and CAT-1041, improve the severe dystrophic phenotype found in both mechanically-damaged mdx mice and a GRMD dog and create an environment that can support more successful muscle regeneration.”

Catabasis’s chief scientific officer Dr Andrew Nichols, added: “We very much appreciate the research performed by Dr Sweeney and his colleagues.

“We agree that these data support edasalonexent as a potential treatment to improve both the quantity and quality of muscle fibers in boys affected by DMD and look forward to the Phase 2 clinical trial results with edasalonexent in the first half of Q1 2017.”

Another DMD firm -  Summit Therapeutics (LON:SUMM) is in a phase II trial with its potentially breakthrough treatment for the disease.

In October, it inked a licensing deal with US biotech Sarepta Therapeutics (NASDAQ:SRPT) worth up to US$522mln.

Shares added 2.49% to US$3.70.

Story by ProactiveInvestors

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.